United Therapeutics Corporation (UT) entered into a Settlement Agreement with Liquidia Technologies, Inc. on October 13, 2026, to resolve pending litigation regarding patent infringement and trade secrets. Under the terms of the agreement, Liquidia will pay United Therapeutics a total of $330.4 million. This payment is broken down into two components: $185 million for past sales of its Yutrepia product for a specific indication, and $145.4 million for continuing sales to patients after the agreement is executed.
The settlement resolves multiple legal disputes, including a case in the U.S. District Court for the District of Delaware where a judge had previously ruled that Liquidia infringed United Therapeutics’ U.S. Patent No. 11,826,327. The agreement also covers litigation in the Middle District of North Carolina and trade secret claims brought against Liquidia and a former executive, Dr. Robert Roscigno. United Therapeutics will retain its claims against Dr. Roscigno as an individual.
In addition to the financial settlement, Liquidia has agreed to remove the pulmonary hypertension associated with interstitial lung disease (PH-ILD) indication from the labeling of its Yutrepia product. The company must file an amendment to its New Drug Application with the FDA to reflect this change. Until the FDA approves the label amendment, Liquidia may continue to sell Yutrepia under its current labeling, but it must immediately cease all marketing, advertising, and promotion activities related to the PH-ILD indication.
Furthermore, Liquidia is restricted from marketing Yutrepia to healthcare practitioners who treat patients with pulmonary arterial hypertension (PAH) only. The company must send letters to pharmacies and healthcare providers instructing them to certify that patients are Group 1 PAH patients and to deny prior authorization requests for Yutrepia for PH-ILD patients. Liquidia must also terminate clinical trial cohorts studying PH-ILD and cease publishing data from those cohorts until the relevant patent expires.
The settlement also addresses litigation involving RareGen, LLC (now Liquidia PAH, LLC) and Sandoz Inc. regarding antitrust claims related to a generic version of Remodulin. United Therapeutics agreed to pay Liquidia $10 million to settle these claims, provided Liquidia secures necessary third-party approvals, such as from Sandoz, to dismiss the litigation.
